Prime Medicine (PRME) Other financing activities (2022 - 2026)

Prime Medicine's Other financing activities history runs 5 years deep, the most recent figure standing at $393000.0 for Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $393000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 93.33% YoY) and the FY2025 annual result came in at $781000.0, down 95.85% from the prior year.
• Other financing activities was $393000.0 for Q1 2026 at Prime Medicine, down from $781000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $17.6 million in Q2 2024 and bottomed at -$68000.0 in Q2 2023.
• A 5-year average of $2.1 million and a median of $293500.0 in 2023 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2023 — Other financing activities grew 24.36% — and 2024, when it jumped 25982.35%.
• Prime Medicine's Other financing activities stood at $156000.0 in 2022, then grew by 24.36% to $194000.0 in 2023, then soared by 8972.16% to $17.6 million in 2024, then plunged by 95.56% to $781000.0 in 2025, then plunged by 49.68% to $393000.0 in 2026.
• Business Quant data shows PRME's Other financing activities at $393000.0 in Q1 2026, $781000.0 in Q4 2025, and $17.6 million in Q2 2024.